2025.10.08 2025.10.08
Pfizer (PFE) Stock Price Forecast: 2025, 2026, 2027–2030 and Beyond

Jana Kanehttps://www.litefinance.org/blog/authors/jana-kane/

Pfizer (#PFE) stocks have garnered considerable attention from investors thanks to their promising upside potential and highly active market conditions. Amid global economic volatility and new healthcare challenges, #PFE offers a compelling option for both short- and long-term investments.

Forecasts for the coming years show a wide range of potential prices, reflecting possible fluctuations and yield increases. Analyzing current trends and seasonal movements presents a unique opportunity to identify optimal market entry points and assess investment risk.

This article provides an in-depth analysis of Pfizer stocks, helping you grasp the intricacies of the market and empowering you to make more informed trading decisions.

Major Takeaways

• The PFE stock price is trading at $26.06 as of 08.10.2025.
• The PFE price reached its all-time high of $61.25 on 16.12.2021. The stock’s all-time low of $0.43 was recorded on 04.10.1974.
• In 2024, the company implemented strategic initiatives to optimize its product lineup and expand its global footprint.
• The PFE stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol #PFE, making it accessible to a wide range of investors.
• The company maintains stable operating profit by actively investing in research and innovation.
• Free cash flow makes it possible to finance new projects and maintain a proper dividend policy.
• In 2025, Pfizer shares are trading at around $26, reflecting stabilization efforts rather than revenue growth or a strengthening of its global position. Annual forecasts point to a wide range of possible scenarios, with no clear signs of a reversal or robust recovery.

Pfizer (PFE) Real-Time Market Status

The current Pfizer (#PFE) stock price is $26.06 as of 08.10.2025.

Investors should monitor key metrics that help assess the financial strength of a company, upside potential, and stock liquidity. For example, market capitalization indicates the overall value of the company, while trading volume reflects market activity. The P/E ratio assesses stock profitability, and the price change over the last 12 months helps to assess the stock’s performance. Additionally, dividend yield and maximum supply help gauge shares’ profitability and availability.

Pfizer (PFE) Stock Price Forecast for 2025–2026 Based on Technical Analysis

Pfizer (PFE) managed to break out of a prolonged sideways trend and consolidate above both moving averages (SMA), regaining its upward momentum. Following a rapid surge in September, the price entered an overbought area. Therefore, it may correct to the middle of the trading channel around $26.5 in October. At the same time, bulls still dominate the market. Trading volume is increasing, and the MACD and RSI indicate a continuation of the uptrend.

In November and December, the PFE stock may gradually move above $28.00, marking the beginning of the battle for the $29.00–$30.00 zone. In the first half of 2026, the price is likely to strengthen, exhibiting short-term corrections. Each correction may provide an opportunity to enter the market. After that, the PFE price is expected to retain the potential to reach new yearly highs. The general trend will likely remain upward as long as Pfizer quotes remain above $25.00–$26.00.

Below are the Pfizer (#PFE) share price estimates for the next 12 months.

Long-Term Trading Plan for PFE for 2025

From a technical standpoint, Pfizer is likely to maintain its gradual growth within the ascending channel in 2025. After a short-term consolidation at the beginning of the year, traders should pay close attention to the $26.00–$26.50 zone, where the key support level is located. This area provides entry points into long positions that can be maintained in the medium term. If the price settles above $28.50, the stock will likely exceed the $30.00 mark.

In 2025, the main scenario suggests opening positions in line with the existing trend, using short-term declines to increase long positions and avoiding counter-trend trades. The first targets for locking in profits may be near $29.50–$30.00, and if volume increases, the bullish target can be shifted to $31.00–$32.00. This scenario should be adjusted if the price plunges below the $25.50 level. As long as PFE quotes remain above the 200-day SMA, the overall sentiment will remain moderately bullish, with the price retaining its potential to reach new highs.

Analysts’ PFE Share Price Projections for 2025

Forecasts for Pfizer’s price in 2025 are based on various analytical approaches. Some estimates suggest a possible gradual recovery in PFE quotes, while others indicate sideways movement. Generally, the consensus forecast suggests cautious optimism for the remainder of the year.

LongForecast

Price range in 2025: $25.33–$36.72 (as of 05.10.2025).

LongForecast predicts moderate growth for Pfizer shares, with a gradual upward shift in the range in December. In mid-autumn, the price is expected to consolidate above $30.00, reflecting stabilizing demand and improving investor sentiment.

CoinCodex

Price range in 2025: $27.10–$37.97 (as of 05.10.2025).

CoinCodex suggests that Pfizer shares will display a smooth upward movement in the last months of 2025. The trading range is expected to expand. The increase in average prices each month signals growth in bullish activity and a strengthening of the short-term uptrend.

StockScan

Price range in 2025: $22.42–$26.66 (as of 05.10.2025).

StockScan offers a more cautious outlook for the Prizer stock in 2025. Analysts predict that PFE shares will remain under pressure at the end of the year, trading in a narrow range. Meanwhile, a short-term recovery cannot be ruled out. The price movement will likely be neutral.

Analysts’ PFE Share Price Projections for 2026

Forecasts for 2026 generally reflect cautious optimism. Most forecasts indicate a gradual strengthening of Pfizer’s share price in the first half of the year, followed by a more robust trend towards the end of the year. This trend is consistent with expectations of a moderate recovery in the pharmaceutical sector.

Note: The price ranges below reflect the expected volatility of the asset over a year. The minimum and maximum prices may not be displayed in the tables.

LongForecast

Price range in 2026: $30.93–$41.34 (as of 05.10.2025).

LongForecast suggests a smooth upward trend throughout the year. After a slight drop in February, analysts expect the asset to strengthen and stabilize near $40.00. The upward movement in the third and fourth quarters will likely be stable, reflecting growing investor demand.

CoinCodex

Price range in 2026: $27.47–$37.04 (as of 05.10.2025).

According to CoinCodex, PFE quotes may fluctuate within a moderately upward range in 2026. A gradual strengthening is forecast in the first half of the year, but a correction is projected in autumn, after which analysts expect the stock to recover closer to December.

StockScan

Price range in 2026: $21.46–$40.37 (as of 05.10.2025).

StockScan notes high volatility in the first half of 2026 and anticipates a likely increase in the PFE stock price by year-end. Following short-lived declines in the spring, growth above $30.00 is assumed in the fourth quarter, mirroring an increased investor appetite for the stock.

Analysts’ PFE Share Price Projections for 2027

Forecasts for 2027 reflect different approaches by analysts to assessing the future movement of Pfizer shares. Predictions range from a price recovery to more neutral movement. It is expected that the Pfizer stock will display elevated volatility throughout the year.

LongForecast

Price range in 2027: $30.83–$48.70 (as of 05.10.2025).

LongForecast predicts that PFE shares will exhibit a gradual strengthening at the beginning of the year. However, the uptrend will likely decelerate closer to autumn. The price movement will alternate between waves of growth and short-lived pullbacks, remaining within a wide trading range. At the same time, analysts assume that the price may recover by the end of the year.

CoinCodex

Price range in 2027: $17.26–$33.32 (as of 05.10.2025).

CoinCodex expects Pfizer quotes to weaken gradually, which may indicate a neutral-bearish scenario and the absence of a pronounced growth momentum.

StockScan

Price range in 2027: $29.60–$50.54 (as of 05.10.2025).

StockScan suggests that PFE will trade within a wide range, exhibiting increased volatility. The forecast notes the possibility of strong fluctuations, but in general, analysts believe a moderately positive scenario is more likely, with potential for growth and subsequent stabilization in the medium term.

Analysts’ PFE Share Price Projections for 2028

Analysts offer different scenarios for Pfizer’s stock performance in 2028. Forecasts range from sideways movement to a gradual decline in the second half of the year. Expectations remain moderate, with no pronounced single direction.

LongForecast

Price range in 2028: $33.66–$48.25 (as of 05.10.2025).

According to LongForecast, the Pfizer stock is expected to decline in 2028. The forecast indicates a decline in quotes by autumn and the formation of a sideways range after moderate strengthening at the beginning of the year. By December, analysts expect a possible stabilization in the range of $36.00–$37.00, indicating a neutral trend.

CoinCodex

Price range in 2028: $16.30–$20.15 (as of 05.10.2025).

CoinCodex assumes that Pfizer shares may remain in a narrow range with a gradual decline in the average price towards the end of the year. Analysts suggest that the PFE market will be characterized by low volatility and a narrow fluctuation range, with modest growth potential estimated.

StockScan

Price range in 2028: $25.96–$44.65 (as of 05.10.2025).

According to StockScan, Pfizer is expected to trade mixed in 2028. In the first half of the year, they expect a significant increase, peaking at around $44.00 in May. In the third and fourth quarters, the stock may weaken, closing in the range of $27.00–$30.00 by the year-end. This scenario points to a likely growth cycle followed by a correction.

Analysts’ PFE Share Price Projections for 2029

Forecasts for 2029 illustrate a cautious outlook. Some forecasts indicate a possible weakening of Pfizer’s stock, while others suggest stabilization after the volatile movements of previous years. The overall sentiment will remain neutral.

Changelly

Price range in 2029: $29.10–$42.61 (as of 05.10.2025).

LongForecast expects Pfizer’s stock to move unevenly throughout the year. Moderate strengthening is forecast for the first half of the year, but the price may decline in the fourth quarter. According to the estimates, the range will remain wide, with no clear long-term trend.

CoinCodex

Price range in 2029: $14.23–$24.77 (as of 05.10.2025).

According to CoinCodex, the Pfizer stock may see a gradual strengthening. In the first half of the year, analysts expect the stock to trade within the range of $14.00–$17.00; however, by December, the price may rise above $24.00. The forecast is based on a scenario of smooth growth without sharp fluctuations.

StockScan

Price range in 2029: $12.93–$28.06 (as of 05.10.2025).

StockScan offers a more pessimistic scenario, in which stocks may remain under pressure for the most part of the year. According to their calculations, prices will gradually decline from $26.00 in January to around $14.00 by December. The forecast reflects expectations of a correctional year with a limited recovery.

Analysts’ PFE Share Price Projections for 2030

Forecasts for 2030 vary widely. Analysts use different forecasting models, spanning from recovery scenarios to assumptions about a long-term decline in the Pfizer stock. The forecast for this period is particularly uncertain.

AuStockExchange

Price range in 2030: $83.62–$99.60 (as of 05.10.2025).

Analysts at AuStockExchange predict steady growth throughout the year. According to their estimates, the trading range will gradually shift higher, and PFE prices may approach the $100.00 mark by the end of December. This scenario reflects expectations of steady growth and strong demand.

CoinCodex

Price range in 2030: $17.89–$23.42 (as of 05.10.2025).

According to CoinCodex, Pfizer shares will trade within a narrow range. Analysts suggest that the market may fluctuate without any significant momentum, with the possibility of gradual strengthening towards the end of the year. The forecast is neutral-positive.

StockScan

Price range in 2030: $2.43–$17.83 (as of 05.10.2025).

StockScan expects the PFE stock to show weak performance. The forecast points to a sharp decline with attempts at short-term recovery in the second half of the year. Analysts anticipate high volatility and remain cautious about the prospects for Pfizer shares.

Analysts’ PFE Share Price Projections until 2050

Long-term forecasts for Pfizer’s share price show significant discrepancies in estimates. Some analysts predict a gradual recovery in PFE value and growth over the next decade, while others point to the possibility of waning demand for the asset amid structural changes in the industry. This difference can be attributed to the long forecasting horizon and the uncertainty surrounding global factors.

According to CoinCodex, by 2040, the average price of Pfizer shares could be around $5.02, and by 2050, it may slide to around $2.44. This scenario reflects a conservative expectation that prices will remain stable, with minimal growth, and exhibit modest dynamics characterized by moderate bullish activity.

The StockScan forecast suggests a more pessimistic scenario. Analysts estimate the average price at $11.62 in 2035, declining to around $9.02 by 2040, and plummeting to around $0.29 by 2050. The range of fluctuations is expected to be wide, from $4.41 to $7.85, indicating a high level of uncertainty. The forecast implies a prolonged downward trend and a gradual decline in the value of shares.

According to AuStockExchange, the picture looks the opposite — the stock will demonstrate a confident strengthening. In 2040, analysts expect a range of $200.70–$220.54, and by 2050, the price may climb to $344.63–$365.25. The scenario suggests a significant long-term recovery in value.

Overall, the forecasts show contrasting expectations. Conservative estimates suggest limited growth and prolonged sideways movement, while optimistic forecasts assume a significant strengthening with a possible breakout to new historical highs.

Market Sentiment for Pfizer (PFE) on Social Media

Media sentiment surrounding Pfizer (PFE) may influence short-term price movements, reflecting the sentiment and expectations of market participants. Discussions on social network X (formerly Twitter) amplify short-term momentum, but they are not a key factor in driving long-term trends. Positive sentiment can support growth, while a surge of doubts leads to transient corrections.

For example, user @TheLongInvestor believes that if Pfizer manages to hold above $25.00, it will confirm the reversal and signal a recovery.

User @FramusM notes that the price may break through the Inverted Head and Shoulders pattern. As a result, the stock may strengthen if bullish momentum is confirmed.

In general, sentiment remains moderately optimistic. Investors believe in a gradual recovery but remain cautious, waiting for prices to firmly consolidate above key levels.

Pfizer (PFE) Price History

Pfizer reached the highest price of $61.25 on 16.12.2021. The lowest price of Pfizer was recorded on 04.10.1974 when the stock declined to $0.43.

The chart below shows the #PFE price performance over the last ten years. It is crucial to evaluate historical data to make our forecasts as accurate as possible.

Pfizer’s share price has hit several key milestones since the early 2000s:

• In 2000, the #PFE price hit a record high of about $50, bolstered by the successful launch of blockbuster drugs such as Viagra, Lipitor, and Zoloft.
• From 2004 to 2009, the #PFE price plunged to $12–$15 due to the company losing several patents and facing heightened competition. Moreover, the global financial crisis of 2008 contributed to these challenges.
• From 2013 to 2019, Pfizer’s share price stabilized in the $35–$45 range thanks to advances in oncology, vaccines, biopharmaceuticals, and a solid dividend policy.
• In 2021, the asset set an all-time high of $61 as sales of Comirnaty, a vaccine developed with BioNTech, generated record revenue for the company.
• In 2023–2025, demand for the vaccine dropped sharply, consequently reducing revenue, and the #PFE price plummeted to $25–$30.
• In 2025, Pfizer shares continue to trade in the $25.00–30.00 range, remaining under pressure from declining vaccine demand and weakening revenues. Market pressure persists, and investor demand remains muted.

The Pfizer stock has historically demonstrated the capacity to recover from severe downturns, indicating future upside potential.

Pfizer (PFE) Fundamental Analysis

Fundamental analysis plays a key role in forecasting the price of any asset. It involves assessing financial data, the company’s market position, and other indicators affecting the #PFE rate.

What Factors Affect the Pfizer (PFE) Stock?

• Financials. The company’s revenues, net income, profitability, and cash flows.
• Development and market launch of new drugs. Successful clinical tests and regulatory approvals.
• Patent protection. Expiration of patents on key drugs, the emergence of generics.
• Mergers and acquisitions. Strategic deals that expand product range and distribution markets.
• Regulatory environment. Changes in healthcare legislation and policy.
• Global economic conditions. Economic crises, currency fluctuations, and geopolitical instability.
• Competition. Actions of major competitors and innovation in the industry.
• Reputational risks. Lawsuits, fines, and public opinion.
• Dividend policy. Changes in the amount and regularity of payments to shareholders.
• Investor sentiment. General trends in the stock market and investors’ attitudes to the pharmaceutical sector.

Given these factors, investors can objectively assess the prospects of the Pfizer stock and make more informed decisions.

More Facts About Pfizer (PFE)

Pfizer Inc. is a prominent American biopharmaceutical company founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York. The company develops, produces, and sells drugs and vaccines to treat various diseases. Pfizer is particularly well-known for its flagship products, such as Lipitor (atorvastatin) to lower cholesterol, Viagra (sildenafil) to address erectile dysfunction, and Prevenar, a pneumococcal vaccine.

In 2020, Pfizer, in collaboration with the German company BioNTech, developed Comirnaty, one of the first COVID-19 vaccines based on mRNA technology, which significantly boosted Pfizer’s global profile. The company is actively investing in research and development to expand its range of innovative medicines and solidify its position in the global pharmaceutical market.

Advantages and Disadvantages of Investing in Pfizer (PFE)

Pfizer is one of the largest pharmaceutical companies, producing popular and effective medications. Moreover, it adheres to a solid dividend policy, making the #PFE stock a safe investment option. However, like any other asset, #PFE carries not only benefits but also risks.

Advantages

• Stable pharmaceutical business. Wide range of high-demand drugs and vaccines.
• Dividend payouts. The yield is above the market average (~5%).
• Innovation leadership. Significant investments in R&D and breakthrough drugs (oncology, vaccines).
• Defensive asset. Demand for drugs remains strong even during crises.
• Global expansion. Operations in key pharmaceutical markets.
• Government support. Cooperation with regulators and research funding.
• Access to new technologies. Regular acquisitions of biotech companies.

Disadvantages

• Declining post-COVID revenues. Falling demand for vaccines and drugs used for COVID-19 treatment.
• Dependence on regulators. FDA approvals and patent litigation can impact revenue.
• Risk of patent expiration. Loss of exclusive rights reduces revenues (Lipitor is an example).
• High competition. Competing with other pharma giants for market and innovation.
• Long development cycle. Clinical tests can take years, and failures lead to significant losses.
• Sensitivity to macroeconomics. Drug price regulation, inflation.
• Stock fluctuations. Despite the stability of this field, the PFE price is susceptible to market trends.

Pfizer (PFE) is a resilient pharmaceutical company known for its solid dividends and opportunities for growth through innovation. However, investors should keep in mind that the stock price might be influenced by factors such as declining post-COVID earnings, upcoming patent expirations, and intense competition. Although the asset is suitable for long-term investments, it is essential to assess the associated risks thoroughly.

How We Make Forecasts

Stock prices are forecast based on three time frames.

• Short-term forecasts (up to 6 months) rely on technical analysis (support/resistance levels, indicators, volumes) and news. Macroeconomic events, reports, and market reactions are taken into account.
• Medium-term forecasts (from 6 months to 3 years) include fundamental analysis (financial indicators, competitive advantages, sales trends). Macroeconomic trends, interest rates, geopolitics, and the company’s product cycle are assessed.
• Long-term forecasts (3 years or more) are focused on strategic analysis. Industry potential, innovation, growth prospects, capital management, and global factors are explored. Besides, discounted cash flow (DCF) models and multiple valuations are also used.

However, each new forecast requires adjustment to align with the latest data and evolving market conditions.

Conclusion: Is Pfizer (PFE) a Good Investment?

According to analysts, Pfizer is undergoing a phase of transition to a post-pandemic environment characterized by slower growth, increased competition, and lower revenues. However, the company maintains a solid foothold, stable dividends, and a long-term focus on research and development. Forecasts offer varying scenarios, but this discrepancy creates room for a flexible approach.

In times of uncertainty, PFE can take its place in a balanced portfolio as a defensive asset with moderate upside potential. Growth potential cannot be ruled out, but it requires patience and a strategic outlook. Pfizer is an investment for those who are betting on stability rather than quick profits.

Price chart of PFE in real time mode